A series of C-suite changes negatively affected the share price of cancer-focused biotech NovoCure (NASDAQ: NVCR) across the ...

Novocure will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open.

PORTSMOUTH — A who’s who of New Hampshire politicians touted cancer-fighting company Novocure during the company’s grand opening ceremony of their North American flagship facility in ...

Novocure Ltd. (NASDAQ:NVCR), a medical technology company specializing in oncology treatments, finds itself at a critical juncture as it navigates market challenges and pipeline opportunities.

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in ...

ROOT, Switzerland, October 01, 2024--Novocure will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. The average of price ...

On Tuesday, NovoCure announced that long-serving CEO Asaf Danziger is stepping down, effective Jan. 1, 2025. He will be replaced by the biotech company's current CFO, Ashley Cordova. Following the ...

Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference ...

Novocure Ltd. (NASDAQ:NVCR), a medical technology company specializing in oncology treatments, finds itself at a critical juncture as it navigates market challenges and pipeline opportunities. The ...

Investors found the announced changes to the company's C-suite unsettling. On Tuesday, NovoCure announced that long-serving CEO Asaf Danziger is stepping down, effective Jan. 1, 2025. He will be ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open.